Cart
sales@molnova.com
Salcaprozate sodium
CAS No. 203787-91-1
Salcaprozate sodium ( SNAC )
Catalog No. M23911 CAS No. 203787-91-1
Salcaprozate sodium is an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 500MG | 53 | In Stock |
|
| 1G | 88 | In Stock |
|
Biological Information
-
Product NameSalcaprozate sodium
-
NoteResearch use only, not for human use.
-
Brief DescriptionSalcaprozate sodium is an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin.
-
DescriptionSalcaprozate sodium is an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin.?It?could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation.
-
SynonymsSNAC
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number203787-91-1
-
Formula Weight301.3
-
Molecular FormulaC15H20NNaO4
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL?(331.88 mM;?Need ultrasonic)
-
SMILESC1=CC=C(C(=C1)C(=O)NCCCCCCCC(=O)[O-])O.[Na+]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Li Y, et, al. Impact of Sodium N-[8-(2-Hydroxybenzoyl)amino]-caprylate on Intestinal Permeability for Notoginsenoside R1 and Salvianolic Acids in Caco-2 Cells Transport and Rat Pharmacokinetics. Molecules. 2018 Nov 16; 23(11):2990.
molnova catalog
related products
-
AZD1208
AZD1208 is a novel, orally bioavailable, highly selective PIM kinase inhibitor with single nanomolar potency against all three PIM kinases.
-
ML355
ML355, a specific, effective 12-Lipoxygenase(12-LOX) inhibitors(IC50=0.34 μM), possess favorable ADME properties.
-
Atrial Natriuretic P...
Atrial natriuretic peptide (ANP), a stimulator of particulate guanylate cyclase, has been found to protect against reoxygenation-induced hypercontracture in isolated cardiomyocytes by increasing cyclic guanosine monophosphate synthesis; ANP also contributes to stimulation of lipolysis during repeated bouts of exercise and in the control of lipolysis during exercise.
